Diabetic cardiomyopathy (DbCM) typically manifests as diastolic dysfunction, and treating heart failure with preserved ejection fraction (HFpEF) is challenging. Empagliflozin (Empa), a sodium–glucose cotransporter 2 inhibitor, reduces hospitalization and mortality in patients with HFpEF and the risk of DbCM. However, the underlying molecular mechanisms and the specific targets remain largely unknown.
Results:
Glutathione peroxidase 4 (GPX4) is a key enzyme that mitigates ferroptosis. Empa treatment improved cardiac function, upregulated GPX4 expression, and reduced ferroptosis in DbCM mice. The ferroptosis inducer erastin abolished the protective effects of Empa. Through database screening, we found that nuclear factor erythroid 2-related factor 2 (NRF2) plays an important role in ferroptosis in DbCM. NRF2 was expressed at lower levels in DbCM mice, and its expression significantly increased after Empa treatment. In NRF2-knockout mice, Empa failed to improve the cardiac function of DbCM mice, upregulate the expression of GPX4, and reduce ferroptosis. Moreover, Empa increased NRF2 levels by inhibiting ubiquitin-mediated degradation. A database search predicted that the stability of NRF2 may be regulated by ubiquitin-specific protease 7 (USP7). Immunoprecipitation assays demonstrated that USP7 interacted with NRF2 and mediated its deubiquitination, thereby stabilizing NRF2. Administration of the USP7 inhibitor P5091 abolished the effects of Empa, whereas the use of adeno-associated virus serotype 9 (AAV9)-NRF2 reversed the effects of P5091.
Innovation and Conclusion:
Empa attenuated cardiomyocyte ferroptosis in DbCM by stabilizing NRF2 through the USP7/NRF2/GPX4 signaling pathway. Targeting the USP7/NRF2/GPX4 pathway may represent a novel therapeutic strategy for attenuating ferroptosis in DbCM, which has clinical significance. Antioxid. Redox Signal. 44, 41–60. Clinical Trials Registration: 2022-SYDWLL-000213.
AbramsonJ, AdlerJ, DungerJ, et al.Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature, 2024; 630(8016):493–500; doi: 10.1038/s41586-024-07487-w
2.
CaiW, ChongK, HuangY, et al.Empagliflozin improves mitochondrial dysfunction in diabetic cardiomyopathy by modulating ketone body metabolism and oxidative stress. Redox Biol, 2024; 69:103010; doi: 10.1016/j.redox.2023.103010
3.
CastroA, BernisC, VigneronS, et al.The anaphase-promoting complex: A key factor in the regulation of cell cycle. Oncogene, 2005; 24(3):314–325; doi: 10.1038/sj.onc.1207973
4.
ChengJ, LiZ, GongR, et al.Molecular mechanism for the substrate recognition of USP7. Protein Cell, 2015; 6(11):849–852; doi: 10.1007/s13238-015-0192-y
5.
ChengT, LiuC, WangY, et al.A novel histone deacetylase inhibitor Se-SAHA attenuates isoproterenol-induced heart failure via antioxidative stress and autophagy inhibition. Toxicol Appl Pharmacol, 2024; 487:116957; doi: 10.1016/j.taap.2024.116957
6.
ChenY, HuaY, LiX, et al.Distinct Types of Cell Death and the Implication in Diabetic Cardiomyopathy. Front Pharmacol, 2020; 11:42; doi: 10.3389/fphar.2020.00042
DhingraR, Rabinovich-NikitinI, RothmanS, et al.Proteasomal Degradation of TRAF2 Mediates Mitochondrial Dysfunction in Doxorubicin-Cardiomyopathy. Circulation, 2022; 146(12):934–954; doi: 10.1161/CIRCULATIONAHA.121.058411
10.
DochertyKF, WelshP, VermaS, et al.; DAPA-HF Investigators and Committees. Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF. Circulation, 2022; 146(13):980–994; doi: 10.1161/CIRCULATIONAHA.122.060511
11.
DodsonM, Castro-PortuguezR, ZhangDD. NRF2 plays a critical role in mitigating lipid peroxidation and ferroptosis. Redox Biol, 2019; 23:101107; doi: 10.1016/j.redox.2019.101107
12.
DuS, ShiH, XiongL, et al.Canagliflozin mitigates ferroptosis and improves myocardial oxidative stress in mice with diabetic cardiomyopathy. Front Endocrinol (Lausanne), 2022; 13:1011669; doi: 10.3389/fendo.2022.1011669
13.
ForandA, KoumakisE, RousseauA, et al.Disruption of the Phosphate Transporter Pit1 in Hepatocytes Improves Glucose Metabolism and Insulin Signaling by Modulating the USP7/IRS1 Interaction. Cell Rep, 2016; 16(10):2736–2748; doi: 10.1016/j.celrep.2016.08.012
14.
FramptonJE. Empagliflozin: A Review in Symptomatic Chronic Heart Failure. Drugs, 2022; 82(16):1591–1602; doi: 10.1007/s40265-022-01778-0
15.
Fuchs AndersenC, OmarM, GlenthøjA, et al.Effects of empagliflozin on erythropoiesis in heart failure: Data from the Empire HF trial. Eur J Heart Fail, 2023; 25(2):226–234; doi: 10.1002/ejhf.2735
16.
GaoM, QiZ, DengM, et al.The deubiquitinase USP7 regulates oxidative stress through stabilization of HO-1. Oncogene, 2022; 41(33):4018–4027; doi: 10.1038/s41388-022-02403-w
17.
GoruSK, KadakolA, PandeyA, et al.Histone H2AK119 and H2BK120 mono-ubiquitination modulate SET7/9 and SUV39H1 in type 1 diabetes-induced renal fibrosis. Biochem J, 2016; 473(21):3937–3949; doi: 10.1042/BCJ20160595
18.
GuanX, WangY, YuW, et al.Blocking Ubiquitin-Specific Protease 7 Induces Ferroptosis in Gastric Cancer via Targeting Stearoyl-CoA Desaturase. Adv Sci (Weinh), 2024; 11(18):e2307899; doi: 10.1002/advs.202307899
19.
GuoNJ, WangB, ZhangY, et al.USP7 as an emerging therapeutic target: A key regulator of protein homeostasis. Int J Biol Macromol, 2024; 263(Pt 1):130309; doi: 10.1016/j.ijbiomac.2024.130309
20.
GuoZ, LinJ, SunK, et al.Deferoxamine Alleviates Osteoarthritis by Inhibiting Chondrocyte Ferroptosis and Activating the Nrf2 Pathway. Front Pharmacol, 2022; 13:791376; doi: 10.3389/fphar.2022.791376
21.
HanJX, LuoLL, WangYC, et al.SGLT2 inhibitor empagliflozin promotes revascularization in diabetic mouse hindlimb ischemia by inhibiting ferroptosis. Acta Pharmacol Sin, 2023; 44(6):1161–1174; doi: 10.1038/s41401-022-01031-0
22.
HeY, JiangS, ZhongY, et al.USP7 promotes non-small-cell lung cancer cell glycolysis and survival by stabilizing and activating c-Abl. Clin Transl Med, 2023; 13(12):e1509; doi: 10.1002/ctm2.1509
23.
HuangQ, TianH, TianL, et al.Inhibiting Rev-erbα-mediated ferroptosis alleviates susceptibility to myocardial ischemia-reperfusion injury in type 2 diabetes. Free Radic Biol Med, 2023; 209(Pt 1):135–150; doi: 10.1016/j.freeradbiomed.2023.09.034
24.
HuT, ZouHX, LeSY, et al.Tanshinone IIA confers protection against myocardial ischemia/reperfusion injury by inhibiting ferroptosis and apoptosis via VDAC1. Int J Mol Med, 2023; 52(5):109; doi: 10.3892/ijmm.2023.5312
KitamuraH. Ubiquitin-Specific Proteases (USPs) and Metabolic Disorders. Int J Mol Sci, 2023; 24(4):3219; doi: 10.3390/ijms24043219
27.
KongQ, QianLL, ZhangL, et al.Empagliflozin Induces Vascular Relaxation in Rat Coronary Artery Due to Activation of BK Channels. Diabetes Metab Syndr Obes, 2024; 17:247–257; doi: 10.2147/DMSO.S419125
28.
LaiW, WangB, HuangR, et al.Ferroptosis in organ fibrosis: From mechanisms to therapeutic medicines. J Transl Int Med, 2024; 12(1):22–34; doi: 10.2478/jtim-2023-0137
29.
LeeKW, ChoJG, KimCM, et al.Herpesvirus-associated ubiquitin-specific protease (HAUSP) modulates peroxisome proliferator-activated receptor γ (PPARγ) stability through its deubiquitinating activity. J Biol Chem, 2013; 288(46):32886–32896; doi: 10.1074/jbc.M113.496331
30.
LeonardiB, MargossianR, ColanSD, et al.Relationship of magnetic resonance imaging estimation of myocardial iron to left ventricular systolic and diastolic function in thalassemia. JACC Cardiovasc Imaging, 2008; 1(5):572–578; doi: 10.1016/j.jcmg.2008.04.005
31.
LiC, ZhangJ, XueM, et al.SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. Cardiovasc Diabetol, 2019; 18(1):15; doi: 10.1186/s12933-019-0816-2
32.
LiG, YangL, FengL, et al.Syringaresinol Protects against Type 1 Diabetic Cardiomyopathy by Alleviating Inflammation Responses, Cardiac Fibrosis, and Oxidative Stress. Mol Nutr Food Res, 2020; 64(18):e2000231; doi: 10.1002/mnfr.202000231
33.
LimCH, FangXQ, KangH, et al.ER Stress-Activated HSF1 Governs Cancer Cell Resistance to USP7 Inhibitor-Based Chemotherapy through the PERK Pathway. Int J Mol Sci, 2024; 25(5):2768; doi: 10.3390/ijms25052768
34.
LinYC, ZhengG, LiuHT, et al.USP7 promotes the osteoclast differentiation of CD14+ human peripheral blood monocytes in osteoporosis via HMGB1 deubiquitination. J Orthop Translat, 2023; 40:80–91; doi: 10.1016/j.jot.2023.05.007
35.
LiQ, ZhaoZ, ZhouX, et al.Ferroptosis: The Potential Target in Heart Failure with Preserved Ejection Fraction. Cells, 2022; 11(18):2842; doi: 10.3390/cells11182842
36.
LiY, XieP, LuL, et al.An integrated bioinformatics platform for investigating the human E3 ubiquitin ligase-substrate interaction network. Nat Commun, 2017; 8(1):347.
37.
LiZ, WuB, ChenJ, et al.WWP2 protects against sepsis-induced cardiac injury through inhibiting cardiomyocyte ferroptosis. J Transl Int Med, 2024; 12(1):35–50; doi: 10.2478/jtim-2024-0004
38.
LiuLB, HuangSH, QiuHL, et al.Limonin stabilises sirtuin 6 (SIRT6) by activating ubiquitin specific peptidase 10 (USP10) in cardiac hypertrophy. Br J Pharmacol, 2022a;179(18):4516–4533; doi: 10.1111/bph.15899
39.
LiuS, BiY, HanT, et al.The E3 ubiquitin ligase MARCH2 protects against myocardial ischemia-reperfusion injury through inhibiting pyroptosis via negative regulation of PGAM5/MAVS/NLRP3 axis. Cell Discov, 2024; 10(1):24; doi: 10.1038/s41421-023-00622-3
40.
LiuY, ZhangQ, YangL, et al.Metformin Attenuates Cardiac Hypertrophy Via the HIF-1α/PPAR-γ Signaling Pathway in High-Fat Diet Rats. Front Pharmacol, 2022b;13:919202; doi: 10.3389/fphar.2022.919202
41.
NandiSS, KatsuradaK, SharmaNM, et al.MMP9 inhibition increases autophagic flux in chronic heart failure. Am J Physiol Heart Circ Physiol, 2020; 319(6):H1414–H1437; doi: 10.1152/ajpheart.00032.2020
42.
PackerM, ButlerJ, ZannadF, et al.Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial. Circulation, 2021; 144(16):1284–1294; doi: 10.1161/CIRCULATIONAHA.121.056824
43.
PeikertA, BartBA, VaduganathanM, et al.Contemporary Use and Implications of Beta-Blockers in Patients With HFmrEF or HFpEF: The DELIVER Trial. JACC Heart Fail, 2024; 12(4):631–644; doi: 10.1016/j.jchf.2023.09.007
44.
QuagliarielloV, De LaurentiisM, ReaD, et al.The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin. Cardiovasc Diabetol, 2021; 20(1):150; doi: 10.1186/s12933-021-01346-y
45.
StelzerG, RosenN, PlaschkesI, et al.The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analyses. Curr Protoc Bioinformatics, 2016; 54:1.30.1–1.30.33; doi: 10.1002/cpbi.5
46.
TangLJ, ZhouYJ, XiongXM, et al.Ubiquitin-specific protease 7 promotes ferroptosis via activation of the p53/TfR1 pathway in the rat hearts after ischemia/reperfusion. Free Radic Biol Med, 2021; 162:339–352; doi: 10.1016/j.freeradbiomed.2020.10.307
47.
TangYJ, ZhangZ, YanT, et al.Irisin attenuates type 1 diabetic cardiomyopathy by anti-ferroptosis via SIRT1-mediated deacetylation of p53. Cardiovasc Diabetol, 2024; 23(1):116; doi: 10.1186/s12933-024-02183-5
48.
TraczM, BialekW. Beyond K48 and K63: Non-canonical protein ubiquitination. Cell Mol Biol Lett, 2021; 26(1):1; doi: 10.1186/s11658-020-00245-6
49.
WangC, ZhuY, ZhuX, et al.USP7 regulates HMOX-1 via deubiquitination to suppress ferroptosis and ameliorate spinal cord injury in rats. Neurochem Int, 2023; 168:105554; doi: 10.1016/j.neuint.2023.105554
50.
WangX, ChenX, ZhouW, et al.Ferroptosis is essential for diabetic cardiomyopathy and is prevented by sulforaphane via AMPK/NRF2 pathways. Acta Pharm Sin B, 2022a;12(2):708–722; doi: 10.1016/j.apsb.2021.10.005
51.
WangX, LiY, HeM, et al.UbiBrowser 2.0: A comprehensive resource for proteome-wide ubiquitin ligase/deubiquitinase-substrate interactions in eukaryotic species. Nucleic Acids Res, 2022b;50(D1):D719–D728.
52.
WangY, WangZ, PengZ, et al.Cocaine and amphetamine-regulated transcript improves myocardial ischemia-reperfusion injury through PI3K/AKT signalling pathway. Clin Exp Pharmacol Physiol, 2024; 51(8):e13904; doi: 10.1111/1440-1681.13904
53.
WangY, YanS, LiuX, et al.PRMT4 promotes ferroptosis to aggravate doxorubicin-induced cardiomyopathy via inhibition of the Nrf2/GPX4 pathway. Cell Death Differ, 2022c;29(10):1982–1995; doi: 10.1038/s41418-022-00990-5
54.
WeiJ, ZhaoY, LiangH, et al.Preliminary evidence for the presence of multiple forms of cell death in diabetes cardiomyopathy. Acta Pharm Sin B, 2022; 12(1):1–17; doi: 10.1016/j.apsb.2021.08.026
55.
WenJ, LiL, YangY, et al.Phytochemicals targeting ferroptosis in cardiovascular diseases: Recent advances and therapeutic perspectives. Phytother Res, 2024; 38(9):4386–4405; doi: 10.1002/ptr.8278
56.
WuQ, YaoQ, HuT, et al.Dapagliflozin protects against chronic heart failure in mice by inhibiting macrophage-mediated inflammation, independent of SGLT2. Cell Rep Med, 2023; 4(12):101334; doi: 10.1016/j.xcrm.2023.101334
57.
XieSY, LiuSQ, ZhangT, et al.USP28 Serves as a Key Suppressor of Mitochondrial Morphofunctional Defects and Cardiac Dysfunction in the Diabetic Heart. Circulation, 2024; 149(9):684–706; doi: 10.1161/CIRCULATIONAHA.123.065603
58.
XueM, LiT, WangY, et al.Empagliflozin prevents cardiomyopathy via sGC-cGMP-PKG pathway in type 2 diabetes mice. Clin Sci (Lond), 2019; 133(15):1705–1720; doi: 10.1042/CS20190585
59.
XuQ, LiuM, GuJ, et al.Ubiquitin-specific protease 7 regulates myocardial ischemia/reperfusion injury by stabilizing Keap1. Cell Death Discov, 2022; 8(1):291; doi: 10.1038/s41420-022-01086-2
60.
YuJ, ZhaoH, QiX, et al.Dapagliflozin Mediates Plin5/PPARα Signaling Axis to Attenuate Cardiac Hypertrophy. Front Pharmacol, 2021; 12:730623; doi: 10.3389/fphar.2021.730623
61.
ZhangS, TianW, DuanX, et al.Melatonin attenuates diabetic cardiomyopathy by increasing autophagy of cardiomyocytes via regulation of VEGF-B/GRP78/PERK signaling pathway. Cardiovasc Diabetol, 2024; 23(1):19; doi: 10.1186/s12933-023-02078-x
62.
ZhangXW, FengN, LiuYC, et al.Neuroinflammation inhibition by small-molecule targeting USP7 noncatalytic domain for neurodegenerative disease therapy. Sci Adv, 2022; 8(32):eabo0789; doi: 10.1126/sciadv.abo0789
63.
ZhaoY, PanB, LvX, et al.Ferroptosis: Roles and molecular mechanisms in diabetic cardiomyopathy. Front Endocrinol (Lausanne), 2023; 14:1140644; doi: 10.3389/fendo.2023.1140644
64.
ZhouN, YuanX, DuQ, et al.FerrDb V2: update of the manually curated database of ferroptosis regulators and ferroptosis-disease associations. Nucleic Acids Res, 2023; 51(D1):D571–D582; doi: 10.1093/nar/gkac935
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
